A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
The purpose of this study is to evaluate the efficacy of Deucravacitinib versus placebo at Week 24 and safety and tolerability of Deucravacitinib versus placebo in adults with Alopecia Areata.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Study to Evaluate Clinical Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants With Alopecia Areata
Actual Study Start Date: November 8, 2022
Estimated Primary Completion Date: September 16, 2024
Estimated Study Completion Date: December 30, 2024
Arm:
- Experimental: Deucravacitinib Dose 1
- Experimental: Deucravacitinib Dose 2
- Placebo Comparator: Placebo, followed by Deucravacitinib Dose 1 or Dose 2.
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Estimated enrolment | 90 |
| Actual Study start date | 08 November 2022 |
| Estimated Study Completion Date | 30 December 2024 |